Sarrazin C - Search Results

1

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure.

Graf C, D'Ambrosio R, Degasperi E, Paolucci S, Llaneras J, Vermehren J, Dultz G, Peiffer KH, Finkelmeier F, Herrmann E, Zeuzem S, Buti M, Lampertico P, Dietz J, Sarrazin C. Graf C, et al. Among authors: sarrazin c. JHEP Rep. 2024 Feb 7;6(3):100994. doi: 10.1016/j.jhepr.2023.100994. eCollection 2024 Mar. JHEP Rep. 2024. PMID: 38357421 Free PMC article.

2

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.

Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Dietz J, et al. Among authors: sarrazin c. J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33220331

3

Expanding epidemic of recently acquired HCV in HIV-coinfected patients over a period of 10 years.

Graf C, Fuhrmann L, Lutz T, Stephan C, Knecht G, Gute P, Bickel M, Peiffer KH, Finkelmeier F, Dultz G, Mondorf A, Wetzstein N, Filmann N, Herrmann E, Zeuzem S, Beerenwinkel N, Dietz J, Sarrazin C. Graf C, et al. Among authors: sarrazin c. JHEP Rep. 2023 Feb 19;5(7):100701. doi: 10.1016/j.jhepr.2023.100701. eCollection 2023 Jul. JHEP Rep. 2023. PMID: 37305441 Free PMC article.

4

Treatment predictors of a sustained virologic response in hepatitis B and C.

Kau A, Vermehren J, Sarrazin C. Kau A, et al. Among authors: sarrazin c. J Hepatol. 2008 Oct;49(4):634-51. doi: 10.1016/j.jhep.2008.07.013. Epub 2008 Jul 31. J Hepatol. 2008. PMID: 18715665 Free article. Review.

5

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy.

Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, Herrmann E, Badenhoop K, Zeuzem S, Sarrazin C. Lange CM, et al. Among authors: sarrazin c. J Hepatol. 2011 May;54(5):887-93. doi: 10.1016/j.jhep.2010.08.036. Epub 2011 Jan 20. J Hepatol. 2011. PMID: 21145801

6

Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.

Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, Zeuzem S, Colombo M, Weiland O, Sarrazin C. Vermehren J, et al. Among authors: sarrazin c. J Hepatol. 2014 May;60(5):913-9. doi: 10.1016/j.jhep.2014.01.002. Epub 2014 Jan 11. J Hepatol. 2014. PMID: 24424305

7

Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.

Peiffer KH, Sommer L, Susser S, Vermehren J, Herrmann E, Döring M, Dietz J, Perner D, Berkowski C, Zeuzem S, Sarrazin C. Peiffer KH, et al. Among authors: sarrazin c. Hepatology. 2016 Jan;63(1):63-73. doi: 10.1002/hep.28255. Epub 2015 Nov 25. Hepatology. 2016. PMID: 26406534

8

Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.

Welker MW, Luhne S, Lange CM, Vermehren J, Farnik H, Herrmann E, Welzel T, Zeuzem S, Sarrazin C. Welker MW, et al. Among authors: sarrazin c. J Hepatol. 2016 Apr;64(4):790-9. doi: 10.1016/j.jhep.2015.11.034. Epub 2015 Nov 30. J Hepatol. 2016. PMID: 26658684

9

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients.

Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C. Peiffer KH, et al. Among authors: sarrazin c. J Infect Chemother. 2018 Jul;24(7):524-530. doi: 10.1016/j.jiac.2018.02.008. Epub 2018 Apr 5. J Infect Chemother. 2018. PMID: 29628383

10

Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study.

Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J. Mücke MM, et al. Among authors: sarrazin c. Open Forum Infect Dis. 2018 Dec 15;6(1):ofy340. doi: 10.1093/ofid/ofy340. eCollection 2019 Jan. Open Forum Infect Dis. 2018. PMID: 30648130 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

418 results

Search Page